Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Status: Closed to Accrual

Learn more:

Abstracts/Posters/Presentations:

  • Nabil Adra, Ralph J. Hauke, Hristos Z. Kaimakliotis, Shuchi Gulati, Neda Hashemi, Roberto Pili. Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Presented as Trials In Progress Poster at the 2020 Genitourinary Cancers Symposium, February 14, 2020. J Clin Oncol 38, 2020 (suppl 6; abstr TPS587). See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.